Episode 2 - Tamiflu Generic, Biosimilars, Pricing and Policy Implications


Fetch error

Hmmm there seems to be a problem fetching this series right now. Last successful fetch was on November 27, 2018 01:34 (2y ago)

What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.

Manage episode 210975249 series 2376277
By whatthepharma. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.

In this episode, I discuss what it means now that Tamiflu generic has been approved and introduced in several markets. Generics and biosimilars are explained within the context of drug development and commercialization. Pricing discussion continues around original v generic/biosimilar drugs and what policy may help more effective pricing. 15 min.

11 episodes